VBL Presents Positive Preclinical Data On Immune Modulator In Rheumatoid ... - Medical News Today (press release)

Oneindia

VBL Presents Positive Preclinical Data On Immune Modulator In Rheumatoid ... Medical News Today (press release) In the mouse model, VB-201 significantly reduced arthritis incidence and severity (as measured by reduced IL-6 plasma levels and significantly less ... Study reveals link between tea and rheumatoid arthritisAustralian Life Scientist Rheumatoid Arthritis on the Rise in WomenFood Consumer Study validates NT-proBNP as strong indicator for cardiovascular risk in ...News-Medical.net MedPage Today all 191 news articles »

ChemoCentryx Can It Be The Next Rheumatoid Arthritis Drug - Examiner.com

Examiner.com

ChemoCentryx Can It Be The Next Rheumatoid Arthritis Drug Examiner.com CCX354 is an oral activated tiny molecule drug competitor devised especially to aim the CCR1 chemokine receptor to treat patients with rheumatoid arthritis ... and more »

Use of Transgenic Mice to Assess the Systemic Effects of Tissue Inhibitor of ... - TechCombo (blog)

Use of Transgenic Mice to Assess the Systemic Effects of Tissue Inhibitor of ... TechCombo (blog) Examples of such diseases include malignant tumors, liver fibrosis, wound healing, rheumatoid arthritis, and a variety of angioproliferative diseases.

Bristol-Myers says arthritis drug trial met goal - Reuters

Bristol-Myers says arthritis drug trial met goal Reuters The molecule, known as BMS-945429/ALD518, is an antibody designed to target a protein called interleukin-6 as a potential treatment for rheumatoid arthritis ... RA drug safety trial successfulPharmacy Europe all 116 news articles »